Insulin Analog Levemir Lowers BG Levels in 60 Percent of Type 2 Patients
Novo Nordisk has announced that results from a study show that almost 60 percent of type 2 patients taking once-daily doses of its Levemir insulin analog were able to reach the average blood sugar level recommended by the American Diabetes Association.
(Levemir is Novo's brand name for insulin detemir, a long-acting manmade insulin analog that acts up to 24 hours to maintain healthy BG levels.)
The study, called TITRATE, involved 244 type 2 diabetes patients who were on oral anti-diabetes drugs and had never before used insulin. They were assigned to one of two treatment groups with different goals as their fasting blood sugar targets: 70 to 90 mg/dl (an A1c of 4% to 4.7%) or 80 to 110 mg/dl (an A1c of 4.4% to 5.4%). The patients continued their use of oral diabetes drugs and learned how to change their Levemir doses every three days in order to close in on their target A1c levels.
The patients had a starting A1c of less than 9%. In the group with the 70 to 90 mg/dl target, 64.3 percent of patients were able to reach the ADA-recommended A1c of less than 7% in 20 weeks. In the 80 to 110 mg/dl target group, 54.5 percent of patients reached the same goal. The overall drop in A1c for the first group was 1.2%, to an average of 6.77%. The second group saw its average A1c drop 0.9% to 7%.
The study found that the rate of minor hypoglycemic events was 5.09 events/patient/year in the 70 to 90 mg/dl target group and 3.16 events/patient/year in the 80 to 110 mg/dl target group. One patient in the 70 to 90 mg/dl group experienced a major hypoglycemic event requiring third party assistance.
The TITRATE study was published online in the journal Diabetes, Obesity & Metabolism.Click Here To View Or Post Comments